New lung drug aims to outshine current treatment in major trial
NCT ID NCT07284602
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This study tests whether a new drug, deupirfenidone, works better than the current standard treatment (pirfenidone) at slowing lung function decline in adults with idiopathic pulmonary fibrosis (IPF). About 1,100 participants will take either drug three times daily for up to a year, with follow-up visits to measure lung health and side effects. Neither participants nor doctors will know which drug is given. The goal is to find a more effective option for managing this progressive lung disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.